Stockscreener 앱 받기
14.93
2.10%
-0.32
시간 외 거래:
14.93
Viatris Inc 주식(VTRS)의 최신 뉴스
UBS raises Viatris stock price target to $20 on cost savings - Investing.com India
UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey
Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Yahoo Finance UK
JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com
Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus
BofA raises Viatris stock price target on cost-cutting plan - Investing.com UK
Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st
Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Yahoo Finance
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan By Investing.com - Investing.com South Africa
Restructuring: Viatris to cut global workforce by about 10% - Pittsburgh Post-Gazette
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy - FinancialContent
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Viatris forecasts 2026 profit below estimates on India manufacturing woes - marketscreener.com
Viatris Launches Major Restructuring After Strong 2025 Results - TipRanks
Viatris maintains annual dividend at 48 cents for 2026 - Investing.com
Viatris shares fall on lower-than-expected 2026 profit outlook - Investing.com Australia
Viatris Posts Narrower Loss In Q4; Expects Workforce Reduction Of Up To Approx. 10% - Nasdaq
Viatris beats on Q4; eyes 10% staff reduction (VTRS:NASDAQ) - Seeking Alpha
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 - TradingView
Viatris: Q4 Earnings Snapshot - marketscreener.com
Viatris beats estimates, stock edges up By Investing.com - Investing.com UK
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results - PR Newswire
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend - PR Newswire
Viatris Inc. Stock Nears 52-Week High Ahead of Q4 Earnings: Shares Climb on Pipeline Strength - International Business Times Australia
Key facts: FDA Accepts Viatris' MR-141 Application; Q4 Results Due Soon - TradingView
Investors await Viatris earnings amid cost-cutting optimism By Investing.com - Investing.com
Viatris Q4 2025 Earnings Preview: Revenue Forecast & Analyst ExpectationsNews and Statistics - IndexBox
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drugs pipeline - Seeking Alpha
FDA accepts Viatris presbyopia treatment application - Investing.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - Seeking Alpha
FDA Accepts Viatris Inc. Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - marketscreener.com
FDA accepts Viatris supplemental new drug application for Mr-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia - marketscreener.com
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia - The AI Journal
FDA Accepts Viatris Supplemental New Drug Application For Mr-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia - TradingView
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow - Yahoo Finance UK
Viatris stock hits 52-week high at $16.31 - Investing.com
Viatris (BIT:1VTRS) Price Target Increased by 12.32% to 11.92 - Nasdaq
Will UBS Upgrade And Inpefa’s First Global Launch Change Viatris' (VTRS) Narrative? - Yahoo Finance
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
What's in Store for These 5 Medical Companies This Earnings Season? - TradingView
Viatris Stock to Report Q4 Earnings: What's in the Cards? - TradingView
Viatris Inc. (VTRS) Investor Outlook: Navigating a 3.02% Dividend Yield Amidst Healthcare Opportunities - DirectorsTalk Interviews
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - MSN
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation - Seeking Alpha
Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Bef - GuruFocus
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline - Finviz
Where is Viatris Inc. (VTRS) headed according to the Street? - MSN
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
(VTRS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Viagra Maker Wins 'Viagor Power' EU TM Battle - Law360
How Do Investors Really Feel About Viatris Inc? - Benzinga
Why Viatris Inc (VTRS) May Struggle to Outperform: A Look at Fut - GuruFocus
Can Viatris Inc. sustain its profitabilityJuly 2025 Levels & Daily Chart Pattern Signals - mfd.ru
Is Viatris Inc. impacted by rising ratesWeekly Trend Summary & Technical Confirmation Alerts - mfd.ru
Is Viatris (VTRS) Quietly Repositioning Its Deal-Making Strategy With a New Chief Legal Officer? - simplywall.st
Viatris (VTRS) Shares Cross 3% Yield Mark - Nasdaq
Viatris Continues Support of SBP, Celebrates Restoration of 250th Home Damaged by Hurricane Maria - CSRwire
Viatris Inc. stock rises Monday, outperforms market - MSN
JPMorgan Adjusts Price Target on Viatris to $16 From $14, Maintains Neutral Rating - marketscreener.com
1.23%
0.23%
자본화:
|
볼륨(24시간):